An overlooked announcement provides an opportunity for a management team that has lost the trust of investors.
News & Analysis: Amyris
The company hopes new products in development and a reshuffled debt portfolio can deliver long-awaited growth and profits. Investors have heard that before.
Another day, another transaction. Is the synthetic biology pioneer better positioned to execute now?
The business received a small lifeline from one of its largest shareholders.
Shares of the synthetic biology pioneer have risen and fallen by double digits many days in recent weeks.
The company reported poor operating performance in 2018, but has attempted to focus the attention of investors on its future.
The company notified the Securities and Exchange Commission that it couldn't file its annual report on time. It gave three reasons.
AMRS earnings call for the period ending December 31, 2018.
Cannabinoids that don't require cannabis just might make these stocks huge winners in the future.
Plants aren't always the perfect medium for producing high-value compounds. Turns out, cannabinoids can be brewed with microbes instead.